

03rd August 2026

To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai- 400001 Scrip Code - 543308 ISIN: INE967H01025	To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Symbol - KIMS ISIN: INE967H01025
--	--

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 03rd August 2026 pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

1. Further to our Board Meeting intimation dated 28th July 2026, the Board of Directors, at their meeting held today, have considered, reviewed deliberated and approved the Unaudited (Standalone and Consolidated) financial results of the Company for the 01st quarter ended 30th June 2026 together with the Limited Review Reports in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, as reviewed by the Audit Committee and enclosed as **Annexure-A**;
2. Further the Board of Directors during the meeting:
 - a) Has approved to advance any loan including any loan represented by a book debt, or give guarantee or provide security in respect of loan taken not exceeding Rs. 650 Crores (Rupees Six Hundred Fifty Crores) over and above the limits available under section 186 of the Companies Act 2013, to any subsidiaries or associate or joint venture or group entity of the Company in which any director is deemed to be interested under Section 185 of the Companies Act, 2013, subject to the approval of the Shareholders of the Company by way of special resolution in the ensuing General Meeting of the company;
 - b) Approved the proposal for extending a loan of up to ₹25 crore (Rupees Twenty-Five Crores) to **KIMS Hospital Enterprises Private Limited**, a material subsidiary of the Company, in accordance with the provisions of the Companies Act, 2013 and other applicable laws;
 - c) Considered and approved the DRAFT O&M agreement and Call Option Agreement as tabled before the board of directors with Golden Lan Solutions Private Limited and Sarwottam Healthcare Private Limited. The requisite SEBI disclosures will be intimated at the time of execution the said definitive agreements accordingly.

Further, the financial results are also available on the website of the Company at [https://www.kimshospitals.com/investors/Disclosures under Regulation 46 of SEBI \(LODR\) Regulations, 2015/ Financial Information/ Financial Result](https://www.kimshospitals.com/investors/Disclosures_under_Regulation_46_of_SEBI_(LODR)_Regulations,_2015/_Financial_Information/_Financial_Result) and on the websites of BSE Ltd and National Stock Exchange of India Ltd viz. www.bseindia.com and www.nseindia.com, respectively.

Krishna Institute of Medical Sciences Limited

D.No.: 1-8-31/1, Minister Road, Secunderabad - 500 003, Telangana, India Phone:
+91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | kimshospitals.com
CIN: L55101TG1973PLC040558



Further, the financial results will also be published in the newspaper as per the requirement and in the format prescribed under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Board Meeting Commenced at : 12.15 P.M.
Board Meeting Concluded at : 04: 15 P.M

This is for your information and records.

Thanking you,

For Krishna Institute of Medical Sciences Limited

Nagajayanthi J.R

Company Secretary & Compliance Officer

Enclosed: As above

Krishna Institute of Medical Sciences Limited

D.No.: 1-8-31/1, Minister Road, Secunderabad - 500 003, Telangana, India Phone:

+91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | kimshospitals.com

CIN: L55101TG1973PLC040558


Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of Krishna Institute of Medical Sciences Limited, Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004



per Mitesh K Parikh

Partner

Membership No.: 225333

UDIN: 26225333ZK11WN8464

Place: Hyderabad

Date: August 03, 2026



Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2026

		(Rupees in millions)			
		Quarter ended		Year ended	
		30-Jun-26 (Unaudited)	31-Mar-26 (Audited) (Refer note 3)	30-Jun-25 (Unaudited)	31-Mar-26 (Audited)
1	Income				
	(a) Revenue from operations	4,836	4,562	3,734	17,015
	(b) Other income	307	176	122	566
	Total Income	5,143	4,738	3,856	17,581
2	Expenses				
	(a) Purchase of medical consumables, drugs and surgical instruments	999	910	781	3,468
	(b) Increase in inventories of medical consumables, drugs and surgical instruments	(39)	(4)	(23)	(135)
	(c) Employee benefits expense	849	720	682	2,907
	(d) Other expenses	1,845	1,631	1,319	6,096
	(e) Finance costs	328	268	125	787
	(f) Depreciation and amortisation expenses	273	255	175	861
	Total Expenses	4,255	3,780	3,059	13,984
3	Profit before tax and exceptional items (1-2)	888	958	797	3,597
4	Exceptional items	-	(67)	-	(70)
5	Profit before tax (3+4)	888	891	797	3,527
6	Tax expense				
	(a) Current tax	200	182	174	745
	(b) Deferred tax charge	23	50	35	175
	Total tax expense (6)	223	232	209	920
7	Profit for the period/year (5-6)	665	659	588	2,607
8	Other comprehensive income/(loss) for the period/year				
	Items that will not be reclassified subsequently to statement of profit and loss				
	- Re-measurement gain/(loss) on defined benefit plans	0	2	(4)	0
	- Income tax effect	(0)	(1)	1	(0)
	Other comprehensive income/(loss), net of tax	0	1	(3)	0
9	Total comprehensive income for the period/year (7+8)	665	660	585	2,607
10	Paid up equity share capital (face value of Rs.2 each)				800
11	Other Equity				23,487
12	Earnings per share (of Rs.2 each) : (not annualised for the quarter ended)				
	(a) Basic (Rs.)	1.66	1.65	1.47	6.52
	(b) Diluted (Rs.)	1.66	1.65	1.47	6.52



Notes:

- The unaudited standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company"), have been prepared in accordance with the Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 ("the Act"), as amended, read with relevant rules thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- The above results for the quarter ended 30 June 2026 of the Company have been reviewed by the Audit committee and approved by the Board of Directors at their meetings held on 03 August 2026 and have been subject to a limited review by the statutory auditors of the Company. The statutory auditors have expressed an unmodified review opinion on these results.
- The standalone figures for the quarter ended 31 March 2026 are the balancing figures between the audited standalone figures in respect of the full financial year ended 31 March 2026 and the published unaudited year to date standalone figures up to the nine months ending 31 December 2025, which were subjected to a limited review by the statutory auditors.
- During the current quarter, the Company issued 19,867,549 equity shares of face value of Rs 2 each through Qualified Institutions Placement (QIP) at an issue price of Rs. 755 per share (including securities premium of Rs. 753 per share), aggregating Rs. 15,000 million. As at 30 June 2026, funds received pursuant to QIP (net of issue expenses of Rs. 237 million) have been utilised towards the objects stated in the Placement Document and the balance amounts unutilised have been temporarily invested in mutual fund and kept in monitoring account.
- The Board of Directors, at its meeting held on 13 June 2026, and shareholders, at their meeting held on 09 July 2026, approved raising of funds through issuance of up to 7,702,182 convertible warrants at an issue price of Rs. 779 per warrant, aggregating up to Rs. 6,000 million ("Convertible Warrants"), on a preferential basis to the promoters and promoter group entities. The warrants shall be payable in cash and are convertible into an equivalent number of fully paid-up equity shares of the Company having face value of Rs. 2 each, in one or more tranches within a period of 18 months from the date of allotment, subject to obtaining necessary regulatory and statutory approvals.
- The Company operates in one single reportable business segment - "Medical and Healthcare services".
- The above Unaudited Standalone Financial Results of the Company are available on the Company's website www.kimshospitals.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.

For and on behalf of the Board
Krishna Institute of Medical Sciences Limited


Dr. B. Bhaskara Rao
Managing Director
DIN: 00008985

Hyderabad
03 August 2026



Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited, Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Krishna Institute of Medical Sciences Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and an associate for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

S No.	Entity	Relationship
1	Krishna Institute of Medical Sciences Limited	Holding Company
2	Arunodaya Hospitals Private Limited	Subsidiary
3	KIMS Hospital Enterprises Private Limited	Subsidiary
4	Iconkrishi Institute of Medical Sciences Private Limited	Subsidiary
5	Saveera Institute of Medical Sciences Private Limited	Subsidiary
6	KIMS Hospital Kurnool Private Limited	Subsidiary
7	KIMS Hospitals Private Limited	Subsidiary
8	KIMS Swastha Private Limited	Subsidiary
9	KIMS Hospital Bengaluru Private Limited	Subsidiary
10	Sarvejana Healthcare Private Limited	Subsidiary
11	SPANV Medisearch Lifesciences Private Limited	Subsidiary
12	KIMS Manavata Hospitals Private Limited	Subsidiary
13	Meda Institute of Podiatry Private Limited	Subsidiary
14	Chalasani Hospitals Private Limited	Subsidiary
15	Kondapur Healthcare Limited	Associate



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes the unaudited interim financial results and other financial information in respect of:
- Three subsidiaries, whose unaudited interim financial results include total revenue of Rs 403 million, total net loss after tax of Rs. 46 million, total comprehensive loss of Rs 46 million, for the quarter ended June 30, 2026, as considered in the statement which have been reviewed by their respective independent auditors.
 - An associate, whose unaudited interim financial results include Group's share of net profit of Rs 10 million and Group's share of total comprehensive profit of Rs 10 million for the quarter ended June 30, 2026, as considered in the Statement whose interim financial results, other financial information have been reviewed by their independent auditor.


The independent auditor's report on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries and associate, is based solely on the report of such auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the work done and the reports of the other auditors.

For S.R. Batliboi & Associates LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004



per Mitesh K Parikh

Partner

Membership No.: 225333

UDIN: 26225333TUNHK67758

Place: Hyderabad

Date: August 03, 2026



Krishna Institute of Medical Sciences Limited

Corporate Identity number : L55101TG1973PLC040558

Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India

Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2026

					(Rupees in millions)
		Quarter ended			Year ended
		30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
		(Unaudited)	(Audited) (Refer note 3)	(Unaudited)	(Audited)
1	Income				
	(a) Revenue from operations	11,795	10,746	8,716	39,046
	(b) Other income	164	97	71	262
	Total Income	11,959	10,843	8,787	39,308
2	Expenses				
	(a) Purchase of medical consumables, drugs and surgical instruments	2,609	2,354	1,917	8,418
	(b) Increase in inventories of medical consumables, drugs and surgical instruments	(162)	(26)	(77)	(329)
	(c) Employee benefits expense	2,126	1,799	1,510	6,817
	(d) Other expenses	4,988	4,554	3,440	16,120
	(e) Finance costs	834	681	326	2,025
	(f) Depreciation and amortisation expenses	1,008	850	534	2,832
	Total Expenses	11,403	10,212	7,650	35,883
3	Profit before share of profit from associate (1-2)	556	631	1,137	3,425
4	Share of profit from associate, net of tax	10	26	-	26
5	Profit before tax and exceptional items (3+4)	566	657	1,137	3,451
6	Exceptional items	-	(109)	-	(112)
7	Profit before tax (5+6)	566	548	1,137	3,339
8	Tax expense				
	(a) Current tax	338	348	324	1,362
	(b) Deferred tax credit	(146)	(131)	(37)	(443)
	Total tax expense (8)	192	217	287	919
9	Profit for the period/year (7-8)	374	331	850	2,420
	Attributable to:				
	Owners of the company	415	425	786	2,414
	Non controlling interests	(41)	(94)	64	6
10	Other comprehensive income/(loss) for the period/year				
	Items that will not be reclassified subsequently to statement of profit and loss				
	- Re-measurement gain/(loss) on defined benefit plans	0	4	(6)	2
	- Income tax effect	0	-	1	-
	Other comprehensive income/(loss), net of tax	0	4	(5)	2
	Attributable to:				
	Owners of the company	0	3	(4)	1
	Non controlling interests	0	1	(1)	1
11	Total comprehensive income				
	Owners of the company	415	428	782	2,415
	Non controlling interests	(41)	(93)	63	7
	Total comprehensive income for the period/year (9+10)	374	335	845	2,422
12	Paid up equity share capital (face value of Rs.2 each)				800
13	Other Equity				21,674
14	Earnings per share (of Rs.2 each): (not annualised for the quarter ended)				
	(a) Basic (Rs.)	1.04	1.06	1.96	6.03
	(b) Diluted (Rs.)	1.04	1.06	1.96	6.03




[Handwritten signature]

Notes:

- 1 The unaudited consolidated financial results of Krishna Institute of Medical Sciences Limited (the "Holding Company" or the "Company"), its subsidiaries (the Company and its subsidiaries together referred to as the "Group") and its associate have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act"), as amended, read with relevant rules thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 The above results for the quarter ended 30 June 2026 of the Group have been reviewed by the Audit committee and approved by the Board of Directors at their meetings held on 03 August 2026 and have been subject to a limited review by the statutory auditors of the Company. The statutory auditors have expressed an unmodified review opinion on these results.
- 3 The Consolidated figures for the quarter ended 31 March 2026 are the balancing figures between the audited Consolidated figures in respect of the full financial year ended 31 March 2026 and the published unaudited year to date Consolidated figures up to the nine months ended 31 December 2025, which were subjected to a limited review by the statutory auditors.
- 4 During the current quarter, the Company issued 19,867,549 equity shares of face value of Rs 2 each through Qualified Institutions Placement (QIP) at an issue price of Rs. 755 per share (including securities premium of Rs. 753 per share), aggregating Rs. 15,000 million. As at 30 June 2026, funds received pursuant to QIP (net of issue expenses of Rs. 237 million) have been utilised towards the objects stated in the Placement Document and the balance amounts unutilised have been temporarily invested in mutual fund and kept in monitoring account.
- 5 The Board of Directors, at its meeting held on 13 June 2026, and shareholders, at their meeting held on 09 July 2026, approved raising of funds through issuance of up to 7,702,182 convertible warrants at an issue price of Rs. 779 per warrant, aggregating up to Rs. 6,000 million ("Convertible Warrants"), on a preferential basis to the promoters and promoter group entities. The warrants shall be payable in cash and are convertible into an equivalent number of fully paid-up equity shares of the Company having face value of Rs. 2 each, in one or more tranches within a period of 18 months from the date of allotment, subject to obtaining necessary regulatory and statutory approvals.
- 6 During the quarter, the Group has entered into a Hospital Operations and Management Agreement with an entity engaged in medical services, thereby obtaining control over hospital operations and providing healthcare services using their assets. The transaction has been accounted for as a business combination under Ind AS 103-Business Combinations ("Ind AS 103") based on provisional purchase price allocation report, with acquisition-related costs of Rs. 3 million included in other expenses.
- 7 The Group operates in one single reportable business segment - "Medical and Healthcare services".
- 8 The above Unaudited Consolidated Financial Results of the Group are available on the Company's website www.kimshospitals.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.

For and on behalf of the Board
Krishna Institute of Medical Sciences Limited


Dr. B Bhaskara Rao
Managing Director

DIN: 00008985

Hyderabad
03 August 2026

